HENRY T AKINBI, M.D.
Medical Practice in Cincinnati, OH

License number
Ohio 35.068202
Category
Medical Practice
Type
Pediatrics
License number
Ohio 35.068202
Category
Medical Practice
Type
Neonatal-Perinatal Medicine
Address
Address
3333 Burnet Ave Ml, Cincinnati, OH 45229
Phone
(513) 636-4830
(513) 636-7868 (Fax)

Personal information

See more information about HENRY T AKINBI at radaris.com
Name
Address
Phone
Henry Akinbi, age 68
1118 Chatham Ct, Cincinnati, OH 45215
(513) 582-2984
Henry T Akinbi, age 68
346 Fleming St, Wyoming, OH 45215
(513) 761-0655
Henry T Akinbi
1118 Chatham Ct, Cincinnati, OH 45215
(513) 761-0655

Professional information

Henry T Akinbi Photo 1

Henry T Akinbi, Cincinnati OH

Specialties:
Neonatal Medicine
Address:
3333 Burnet Ave SUITE 4058, Cincinnati 45229
(513) 636-4830 (Phone), (513) 636-7868 (Fax)
Cincinnati Office
3333 Burnet Ave, Cincinnati 45229
(513) 636-4751 (Phone), (513) 636-8145 (Fax)
Certifications:
Pediatrics, 1991, Perinatal Medicine & Neonatal Medicine, 2003
Awards:
Healthgrades Honor Roll
Languages:
English
Education:
Medical School
University of Ife / Faculty of Health Sciences
Children's Hospital Philadelphia
Moses H Cone Mem Hospital
University Of Nc Hosps


Henry T Akinbi Photo 2

Henry T Akinbi, Cincinnati OH

Specialties:
Neonatal-Perinatal Medicine Specialist
Address:
3333 Burnet Ave, Cincinnati, OH 45229
Education:
Bachelor of Medicine, Bachelor of Surgery
Board certifications:
American Board of Pediatrics Sub-certificate in Neonatal-Perinatal Medicine (Pediatrics)


Henry Akinbi Photo 3

Lysozyme Fusion Proteins In Infections

US Patent:
5993809, Nov 30, 1999
Filed:
Nov 18, 1998
Appl. No.:
9/193877
Inventors:
Timothy Edward Weaver - Loveland OH
Henry Toyin Akinbi - Cincinnati OH
Assignee:
Children's Hospital Medical Center - Cincinnati OH
International Classification:
A61K 3816, A61K 3843, A61K 3847
US Classification:
424 9461
Abstract:
A method and composition for prophylaxis and/or treatment of bacterial infections, particularly bacterial respiratory infections. A fusion protein of lysozyme and the carboxyl terminal propeptide of surfactant protein-B (SP-B) with the preceding ten amino acids of the mature SP-B peptide is administered in a pharmaceutically acceptable medium to an individual. The fusion protein may be selected so as to deliver it to a target infection site, such as the lungs or gastrointestinal tract. The method and composition eliminates problems associated with conventional antibiotic treatments, such as inefficacy and promotion of antibiotic resistant bacterial strains.